Tsubota Hideki, Ribeiro Roberto V P, Billia Filio, Cusimano Robert J, Yau Terrence M, Badiwala Mitesh V, Stansfield William E, Rao Vivek
From the Advanced Heart Failure Program, Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ont.
Can J Surg. 2017 Aug;60(4):253-259. doi: 10.1503/cjs.011316.
As support times for left ventricular assist devices (LVADs) become longer, several complications requiring device exchange may occur. To our knowledge, this is the first Canadian report regarding implantable LVAD exchange.
We retrospectively reviewed the cases of consecutive, unique patients implanted with an LVAD between June 2006 and October 2015 at Toronto General Hospital.
In total, 122 patients were impanted with an LVAD during the study period. Eight patients required LVAD exchange, and 1 patient had 2 replacements (9 of 122, 7.3%). There were 7 HeartMate II (HMII), 1 HVAD and 1 DuraHeart pumps exchanged. Two of these exchanges occurred early at the time of initial implant, whereas 7 occurred late (range 8-623 d). Six exchanges were made owing to pump thrombosis. Of the 3 exchanges made for other causes, 1 HMII exchange was owing to a driveline fracture, 1 DuraHeart patient had early inflow obstruction requiring exchange to HMII at the initial implant, and the third had a suspected inflow obstruction with no evidence of thrombosis at the time of the procedure. The mean support time before exchange was 225 days, and time from exchange to transplant, death or ongoing support was 245 days. Three patients were successfully bridged to transplant, and at the time of data collection 2 were supported awaiting transplant. Three patients died after a mean duration of 394.3 days (range 78-673 d) of support postreplacement. Four cases were successfully performed using a subcostal approach.
Pump thrombosis is the most common cause for LVAD exchange, which can be performed with acceptable morbidity and mortality. The subcostal approach may be the preferred procedure for an HMII exchange when indicated.
随着左心室辅助装置(LVAD)的支持时间延长,可能会出现一些需要更换装置的并发症。据我们所知,这是加拿大第一份关于植入式LVAD更换的报告。
我们回顾性分析了2006年6月至2015年10月在多伦多综合医院连续植入LVAD的独特患者病例。
在研究期间,共有122例患者植入了LVAD。8例患者需要更换LVAD,1例患者进行了2次更换(122例中的9例,7.3%)。共更换了7台HeartMate II(HMII)、1台HVAD和1台DuraHeart泵。其中2次更换发生在初次植入时的早期,而7次发生在后期(范围为8 - 623天)。6次更换是由于泵血栓形成。在因其他原因进行的3次更换中,1次HMII更换是由于驱动线骨折,1例DuraHeart患者在初次植入时早期出现流入道梗阻,需要更换为HMII,第3例在手术时怀疑有流入道梗阻,但无血栓形成证据。更换前的平均支持时间为225天,更换至移植、死亡或持续支持的时间为245天。3例患者成功过渡到移植,在数据收集时,2例患者仍在等待移植支持。3例患者在更换后平均支持394.3天(范围为78 - 673天)后死亡。4例手术采用肋下途径成功完成。
泵血栓形成是LVAD更换最常见的原因,该操作的发病率和死亡率可以接受。在有指征时,肋下途径可能是HMII更换的首选方法。